Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutant NSCLC: A Post Hoc Subgroup Analysis From PACIFIC

杜瓦卢马布 医学 内科学 肿瘤科 子群分析 析因分析 放化疗 阶段(地层学) 养生 置信区间 癌症 总体生存率 免疫疗法 无容量 生物 古生物学
作者
Jarushka Naidoo,Scott Antonia,Yi−Long Wu,Byoung Chul Cho,Piruntha Thiyagarajah,Helen Mann,Michael Newton,C. Faivre‐Finn
出处
期刊:Journal of Thoracic Oncology [Elsevier BV]
卷期号:18 (5): 657-663 被引量:56
标识
DOI:10.1016/j.jtho.2023.02.009
摘要

Consolidation durvalumab (the "PACIFIC regimen") is standard of care for patients with unresectable stage III NSCLC who have not progressed after chemoradiotherapy, on the basis of data from the phase 3 placebo-controlled PACIFIC study (NCT02125461). Nevertheless, the benefit of immunotherapy in patients with stage III EGFR-mutant (EGFRm) NSCLC is not well characterized. Here, we report a post hoc exploratory efficacy and safety analysis from a subgroup of patients with EGFRm NSCLC from the PACIFIC.Patients with stage III unresectable NSCLC and no progression after more than or equal to two cycles of platinum-based concurrent chemoradiotherapy were randomized (2:1) to receive durvalumab (10 mg/kg intravenously every 2 weeks [wk], for up to 1 y) or placebo; stratified by age, sex, and smoking history. Enrollment was not restricted by oncogenic driver gene mutation status or programmed death-ligand 1 expression. Patients with NSCLC with an EGFR mutation, determined by local testing only, were included in this subgroup analysis. The primary end points were progression-free survival (PFS; assessed by blinded independent central review) and overall survival (OS). Secondary end points included objective response rate and safety. Statistical analyses for the subgroup of patients with EGFRm NSCLC were post hoc and considered exploratory.Of 713 patients randomized, 35 had locally confirmed EGFRm NSCLC (durvalumab, n = 24; placebo, n = 11). At data cutoff (January 11, 2021), median duration of follow-up for survival was 42.7 months (range: 3.7-74.3 mo) for all randomized patients in the subgroup. Median PFS was 11.2 months (95% confidence interval [CI]: 7.3-20.7) with durvalumab versus 10.9 months (95% CI: 1.9-not evaluable [NE]) with placebo; hazard ratio = 0.91 (95% CI: 0.39-2.13). Median OS was 46.8 months (95% CI: 29.9-NE) with durvalumab versus 43.0 months (95% CI: 14.9-NE) with placebo; hazard ratio = 1.02 (95% CI: 0.39-2.63). The safety profile of durvalumab was generally consistent with the overall population and known profile for durvalumab.PFS and OS outcomes with durvalumab were similar to placebo for patients with EGFRm tumors, with wide CIs. These data should be interpreted with caution owing to small patient numbers and lack of a prospective study that evaluates clinical outcomes by tumor biomarker status. Further research to determine the optimal treatment for unresectable stage III EGFRm NSCLC is warranted.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
梓歆发布了新的文献求助10
2秒前
顺利一德发布了新的文献求助10
2秒前
3秒前
量子星尘发布了新的文献求助10
4秒前
隐形曼青应助半糖采纳,获得10
5秒前
静文发布了新的文献求助10
5秒前
溪夕er完成签到,获得积分10
7秒前
SSS水鱼发布了新的文献求助10
8秒前
ACE发布了新的文献求助10
8秒前
9秒前
splemeth完成签到,获得积分10
10秒前
桐桐应助liars采纳,获得10
11秒前
yishan101完成签到,获得积分10
12秒前
13秒前
可靠觅珍应助高大的依秋采纳,获得30
15秒前
15秒前
16秒前
澡雪发布了新的文献求助10
16秒前
大模型应助YXC采纳,获得10
17秒前
17秒前
蟪蛄鸪完成签到 ,获得积分20
18秒前
18秒前
Bryan应助科研通管家采纳,获得10
20秒前
科研通AI5应助科研通管家采纳,获得10
20秒前
FashionBoy应助科研通管家采纳,获得10
21秒前
饱满南松发布了新的文献求助10
21秒前
乐乐应助科研通管家采纳,获得10
21秒前
丘比特应助科研通管家采纳,获得10
21秒前
领导范儿应助科研通管家采纳,获得10
21秒前
852应助科研通管家采纳,获得10
21秒前
Owen应助科研通管家采纳,获得30
21秒前
Bryan应助科研通管家采纳,获得10
21秒前
Akim应助科研通管家采纳,获得10
21秒前
乐乐应助科研通管家采纳,获得10
21秒前
花花发布了新的文献求助10
23秒前
多金完成签到,获得积分10
23秒前
闪电侠完成签到 ,获得积分10
24秒前
25秒前
多金发布了新的文献求助10
26秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3975516
求助须知:如何正确求助?哪些是违规求助? 3519930
关于积分的说明 11200130
捐赠科研通 3256278
什么是DOI,文献DOI怎么找? 1798183
邀请新用户注册赠送积分活动 877425
科研通“疑难数据库(出版商)”最低求助积分说明 806320